INTRODUCTION
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin's lymphoma (NHL) after diffuse large B-cell lymphoma (DLBCL). It accounts for approximately 20 .3% of NHL cases among Saudi adults in 2011. It affected 42 (11.0%) males and 27 (9.3%) females out of 744 NHL cases. The annual number of cases of this disease has increased from 34 in 2001 to 69 in 2011. [1] 
METHODS
A committee comprising experts in hematology and medical oncology was established under the supervision of the Saudi Lymphoma Group and in collaboration with the Saudi Oncology Society. For collecting evidence, a literature search was carried out with relevant keywords using online database search engines such as PubMed/Medline, Web of Science and Scopus. In addition, expert opinion was considered when necessary.
The levels of evidence used in developing this guideline were as follows:
• Evidence level (EL)-1 (highest), evidence from Phase III randomized trials or meta-analyses • EL-2 (intermediate), evidence from well-designed Phase II trials or Phase III trials with limitations • EL-3 (low), evidence from retrospective or observational studies/reports and/or expert opinion.
This easy-to-follow grading system is convenient for readers to understand and allows an accurate assessment of the guideline's applicability in individual patients.
[2]
1. DIAGNOSIS 1.1. Excisional biopsy is the optimal approach for initial diagnosis of FL. Typically, it has a distinctly nodular growth pattern and is comprised of a mixture of centrocytes and centroblasts. Partially involved lymph nodes can also be seen (EL-1).
[3]
1.2. Tumor grade [ Table 1 ] and Follicular Lymphoma International Prognostic Index (FLIPI) are the best tools to predict the outcome of newly diagnosed patients (EL-1). [4, 5] 1.3. Almost all cases are positive for CD19, CD20, CD79a, CD21, and CD10 (60%), but lack expression of CD5, CD43, and CD11c. CD23 expression is variable but typically negative (EL-1). [3, 6, 7] 1.4. BCL-2 protein is strongly positive in almost all Grades 1 and 2 subtypes. BCL-6 is expressed by at least some of the neoplastic cells in all FL tumors (EL-1). [8, 9] 1.5. Fine needle aspiration should be avoided for diagnosing FL, as it does not allow to determine the typical growth pattern and grading of the disease (EL-3). [11, 12] 4.1.1. Stages I and II: Grades 1, 2 or 3a: 4.1.1.1 A potential curative radiation therapy to all involved tumor sites is the preferred option With this approach, the 10-year overall survival (OS) is the range of 60-80% (median, about 19 years) (EL-1).
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[13] rituximab and bendamustine (RB) (EL-1). [22, 23] Obinutuzumab-based chemotherapy is another option (EL-1).
[24]
R-CHOP is also a viable first-line treatment option (EL-1).
[ 25] 4.2.5 Despite the high efficacy of the above-mentioned conventional first-line regimens, none are curative given that the 10-year OS of FL patients is about 70%. [26] 4.2.6 In patients with significant comorbidities and those who are not candidates for such combination regimens but have slow tumor dynamic, a single agent rituximab is an acceptable option (EL-3). In has been found that patients receiving once-weekly rituximab for four consequent weeks had improved quality of life in asymptomatic, advanced-stage and low-tumor-burden FL patients compared with the observation only group (EL-1). [19] 4.2.7 Similar results were obser ved when high-dose chemotherapy and autologous stem cell transplantation was performed in the management of newly diagnosed patients with high-risk FL. Prospective randomized and retrospective studies have found that these treatment options do improve the PFS but not OS (EL-1). [27] [28] [29] [30] 4.3. Maintenance with rituximab after first-line treatment 4.3.1 In the PRIMA trial, as compared with placebo, patients on maintenance with rituximab (375 mg/m 2 every 2 months for 2 years) after RCHOP and RCVP improved PFS (75% and 58%, respectively) (EL-1). [31] 4.3.2 There are no supportive data from randomized trials to advocate the use of rituximab after RB (EL-3).
4.4. Management of relapsed and refractory disease 4.4.1 The tools to assess indication for initiating first-line treatment are generally also applicable in relapsed patients (EL-1). [20, 21] 4.4.2 Therefore, treatment would not immediately begin for all relapse cases, unless there is an indication [ Table 3 ] (EL-1). [20, 21] 4.4.3 Lymph node biopsy should be performed if transformation is suspected. The positron emission tomography-CT may be useful in determining lymph node for biopsy (EL-3). 4.4.4 The most widely used regimens are s i n g l e -a g e n t r i t u x i m a b, RC H O P, 4.1.1.2 Adding rituximab or chemotherapy to radiation improves progression-free survival (PFS) but not OS (EL-1). [14, 15] 4.1.1.3 In patients with the non-bulky disease, if radiation is not feasible (in areas with expected significant radiation-induced morbidity), observation is a reasonable option (EL-3). [16, 17] 4.1.1.4 In patients with the bulky (>5 cm) limited stage disease, there is need f o r s y s t e m i c t r e a t m e n t w i t h immunochemotherapy used in advanced stages, or immunotherapy with or without radiation (EL-2).
[ 18] 4.1.2. Grade 3b: 4.1.2.1 The consensus is to treat this group of patients as those with DLBCL; i.e. combined immunochemotherapy with rituximab plus cyclophosphamide, v i n c r i s t i n e , d o x o r u b i c i n a n d prednisone (R-CHOP) for six cycles followed by two additional rituximab applications (EL-3). 4.1.2.2 Another option is three to four cycles of R-CHOP followed by radiation (EL-3).
4.2. Advanced stages 4.2.1 In patients with low tumor burden and advanced stages, it is not necessary to initiate chemotherapy. However, these patients need to be followed-up regularly, as some may experience spontaneous remission (EL-1). [19] 4.2.2 In patients with high tumor burden and those fulfilling the GELF (Groupe d-Etude des Lymphomes Folliculaires) [20] and/or BNLI criteria (British National Lymphoma Investigation), [21] treatment should be initiated [ Table 3 ] (EL-1). 4.2.3 The preferred regimen for advanced stages is combined immunochemotherapy with RCVP, rituximab, f ludarabine and mitoxantrone (RFM), rituximab and bendamustine (RB) or obinutuzumab plus RB, depending on the first-line therapy and duration of response after the initial treatment (EL-1). [19, 22, 25, [32] [33] [34] 4.4.5 A few studies have found encouraging results with when novel agents such as lenalidomide or bortezomib have been used in combination with rituximab or immunochemotherapy (EL-2). [35, 36] 4.4.6 Radiation is also an option in selected patients with localized relapse (EL-3). 4.4.7 The role of maintenance therapy with rituximab in relapsed patients who had received rituximab as first-line therapy is unclear. [37] 4.4.8. The role of autolog ous stem cell transplantation in relapsed patient is unclear. [38] 4.4.9. Allogeneic transplantation should be limited to selected young patients. Non-myeloablative approach is preferred over myeloablative regimens, which should be limited to highly selected young patients with relapsed FL. [39, 40] 4.5. Follow-up 4.6.1. Every 3 months for 2 years, then every 6 months for 3 years, and then annually. 4.6.2. History and physical examination should be documented in each visit. 4.6.3. CBC with differential count and LDH evaluations should be requested in each visit. 4.6.4. Thyroid-stimulating hormone (TSH) test should be carried out at least once annually if the patient had received radiotherapy to the neck. 4.6.5. CT of neck and CAP is required after completion of therapy, and if the findings are normal, no further routine imaging is required. 4.6.6. Mammogram should be done for women who received chest radiotherapy, beginning 10 years after the diagnosis of FL or at the age of 40 years, whichever comes first. 4.6.7. Annual influenza immunization is recommended (EL-3).
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